New shot aims to boost platelets in ITP patients
NCT ID NCT06880081
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive a single injection of PN20, which is designed to stimulate platelet production. The main goal is to check safety and see if platelet counts improve within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PN20 (thrombopoietin receptor agonist)
What this could lead to
If successful, this could point toward a new treatment option to raise platelet counts and reduce bleeding risk in people with ITP.
What could go wrong
This is a very early, small Phase 1b trial with only 12 participants, so results may not apply broadly. The main goal is safety, not proof of effectiveness, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, 550004, China
Contact
-
Hematology Hospital of Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 301609, China
Contact
-
Jining First People's Hospital
RECRUITINGJining, Shandong, 272011, China
Contact
-
The Second Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, 650000, China
Contact
-
The Second Affiliated Hospital of Nanchang University
RECRUITINGNanchang, Jiangxi, 330006, China
Contact